Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N4O2.C5H7NO3 |
Molecular Weight | 303.3149 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CCC(=O)N1.N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=UYCAGRPOUWSBIQ-WOYAITHZSA-N
InChI=1S/C6H14N4O2.C5H7NO3/c7-4(5(11)12)2-1-3-10-6(8)9;7-4-2-1-3(6-4)5(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);3H,1-2H2,(H,6,7)(H,8,9)/t4-;3-/m00/s1
Molecular Formula | C5H7NO3 |
Molecular Weight | 129.114 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C6H14N4O2 |
Molecular Weight | 174.201 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628 |
44.1 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6219 μM |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
882 μM |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
310 μM |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
265435 M × min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
38223 M × min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
24788 M × min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41.6 min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
59.6 min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
77.5 min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% EXPERIMENT https://www.jci.org/articles/view/103568 |
ARGININE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: |
unhealthy, 1.75 |
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Cardiopulmonary arrest Sources: Metabolic acidosis (acute) Hyponatremia (severe) |
200 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 200 mg/kg, 3 times / day Route: oral Route: multiple Dose: 200 mg/kg, 3 times / day Sources: |
unhealthy, 24 |
|
15 g 2 times / day multiple, oral Studied dose Dose: 15 g, 2 times / day Route: oral Route: multiple Dose: 15 g, 2 times / day Sources: |
healthy, 34 ± 2.6 |
|
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: |
unhealthy, 43± 16 |
DLT: Gastrointestinal discomfort... Dose limiting toxicities: Gastrointestinal discomfort (20%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiopulmonary arrest | Disc. AE | 3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: |
unhealthy, 1.75 |
Metabolic acidosis | acute Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: |
unhealthy, 1.75 |
Hyponatremia | severe Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: |
unhealthy, 1.75 |
Gastrointestinal discomfort | 20% DLT |
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: |
unhealthy, 43± 16 |
PubMed
Title | Date | PubMed |
---|---|---|
Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes. | 2001 |
|
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. | 2001 |
|
Purification and characterization of calobin II, a second type of thrombin-like enzyme from Agkistrodon caliginosus (Korean viper). | 2001 Apr |
|
Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF. | 2001 Apr 20 |
|
Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. | 2001 Apr 6 |
|
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. | 2001 Feb |
|
Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. | 2001 Feb |
|
Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoprotein. | 2001 Feb 16 |
|
Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. | 2001 Feb 2 |
|
DNA recognition by the methyl-CpG binding domain of MeCP2. | 2001 Feb 2 |
|
Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of the catalytic activity of glutathione transferases. | 2001 Feb 23 |
|
Influence of microcystin-YR and nodularin on the activity of some proteolytic enzymes in mouse liver. | 2001 Feb-Mar |
|
Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells. | 2001 Jan |
|
Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. | 2001 Jan |
|
Effect of AVT antisense oligodeoxynucleotides on AVT release induced by hypertonic stimulation in chicks. | 2001 Jan |
|
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. | 2001 Jan |
|
An extended hydrophobic interactive surface of Yersinia pestis Caf1M chaperone is essential for subunit binding and F1 capsule assembly. | 2001 Jan |
|
Relationship between flow rate and NO production in postnatal mesenteric arteries. | 2001 Jan |
|
Altered TNF-alpha, glucose, insulin, and amino acids in islets of Langerhans cultured in a microgravity model system. | 2001 Jan |
|
Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. | 2001 Jan |
|
Buffering action of endogenous nitric oxide on the adrenocortical secretagogue effect of endothelins in the rat. | 2001 Jan |
|
In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. | 2001 Jan |
|
Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. | 2001 Jan |
|
Nitric oxide production by coelomocytes of Asterias forbesi. | 2001 Jan |
|
Specific interactions at the regulatory domain-substrate binding domain interface influence the cooperativity of inhibition and effector binding in Escherichia coli D-3-phosphoglycerate dehydrogenase. | 2001 Jan 12 |
|
Insights into the molecular basis for the carbenicillinase activity of PSE-4 beta-lactamase from crystallographic and kinetic studies. | 2001 Jan 16 |
|
Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine. | 2001 Jan 19 |
|
A proposed common structure of substrates bound to mitochondrial processing peptidase. | 2001 Jan 19 |
|
Site-specific single amino acid changes to Lys or Arg in the central region of the movement protein of a hybrid bromovirus are required for adaptation to a nonhost. | 2001 Jan 5 |
|
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. | 2001 Jan 5 |
|
Membrane binding motif of the P-type cardiotoxin. | 2001 Jan 5 |
|
The function of Arg-94 in the oxidation and decarboxylation of glutaryl-CoA by human glutaryl-CoA dehydrogenase. | 2001 Jan 5 |
|
L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. | 2001 Jan 5 |
|
Rapid kinetic studies link tetrahydrobiopterin radical formation to heme-dioxy reduction and arginine hydroxylation in inducible nitric-oxide synthase. | 2001 Jan 5 |
|
A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp. PCC 7119 is required for efficient reduction of photosystem I. | 2001 Jan 5 |
|
The modulation of oxygen radical production by nitric oxide in mitochondria. | 2001 Mar 9 |
|
Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R. | 2001 Mar 9 |
|
Identification of the bile acid-binding site of the ileal lipid-binding protein by photoaffinity labeling, matrix-assisted laser desorption ionization-mass spectrometry, and NMR structure. | 2001 Mar 9 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/l-arginine.html
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride.
https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:55:52 GMT 2025
by
admin
on
Mon Mar 31 19:55:52 GMT 2025
|
Record UNII |
808T94CEU6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3271 (Number of products:37)
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
808T94CEU6
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
100000089102
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
808T94CEU6
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
260-081-5
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
L-Arginine L-pyroglutamate
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
DTXSID50971695
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
1482633
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB23582
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
198346
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY | |||
|
56265-06-6
Created by
admin on Mon Mar 31 19:55:52 GMT 2025 , Edited by admin on Mon Mar 31 19:55:52 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |